CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm. » Read More
GSK CEO Sir Andrew Witty outlines the key factors to take away from the company’s latest earnings, saying it’s on-track to get a margin above 30 percent.
GSK CEO Sir Andrew Witty explains why he still believes the U.K. is better off in the EU.
Will GSK cave in to critics’ pressure and sell off chunks of its business? Its CEO, Sir Andrew Witty, weighs in.
GSK CEO, Sir Andrew Witty says he’s delighted with the progress and the vast majority of the new products that GSK has delivered in terms of sales.
Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline's sales figures 8 percent.
BP's message to other oil companies in the first quarter was loud and clear, CNBC's Jim Cramer says.
Fred Hassan, Warburg Pincus, talks drug pricing and how it is playing out in an election year.
Fred Hassan, Warburg Pincus, discusses the Treasury Department's crackdown on inversions and weighs in on overhauling the U.S. tax system and the corporate tax rate.
I think he will find his base at Valeant, says Fred Hassan, Warburg Pincus, talking about Joseph Papa, the newly appointed CEO of Valeant.
CNBC's Meg Tirrell reports on an FDA advisory committee's vote to decline the sale of an experimental drug to treat Duchenne muscular dystrophy.
Inventor of aspirin and maker of Yasmin birth control pills says it still expects adjusted EBITDA to increase this year.
Advisers to the FDA voted on Monday not to recommend approval of possibly the first drug for Duchenne muscular dystrophy, the New York Times reports.
Sarepta interim CEO Ed Kaye reacts to FDA panel's negative decision on data supporting approval of Duchenne muscular dystrophy drug.
CNBC's Meg Tirrell looks into Valeant Pharma's appointment of Joseph Papa to CEO, as well as Sarepta's showdown with the FDA over a muscular dystrophy drug.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Sarepta Therapeutics's Eteplirsen is in front of the FDA advisory committee today for a vote on whether the drug is effective in treating Duchenne muscular dystrophy, reports CNBC's Meg Tirrell.
Theranos offers a reminder of the perils of investing in Silicon Valley, where it's common for founders to control a company, the NYT reports.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
Raghuram Selvaraju, H.C. Wainwright senior biotechnology analyst, talks about Valeant offering the CEO position to Perrigo's Joseph Papa.
Get the best of CNBC in your inbox